Pfizerâ€™s New Drug Shows Potential to Prevent Metastatic Disease
Pfizer, the largest research-based pharmaceutical company in the world, has developed a new drug dubbed PD 0332991. It is being claimed after a trial of the same that it has the potential to stop aggressive breast cancer in progress.
The team says that the occurrence of the same is prevented for more than two years i. e. for a median of 26.1 months. However, if femara is given alone, patients could prevent the development of an incurable form of the disease for only 7.5 months.
The findings had been recently presented at the San Antonio Breast Cancer Symposium, which had involved some 165 patients with metastatic disease. All of them were given PD 0332991 along with Novartis (NOVN) AG's Femara.
Metastatic disease is the one in which cancer tends to spread to all other body parts of the patients, the report finds in the meanwhile. The same needs to be addressed sooner as possible since thousands of women are living with devastating conditions and dying as well.
It was noted that the drug was effective as well as safe. However, a larger trial is now being urged so as to confirm the benefits. "There will be gaps in our knowledge of how to give it and when. We're trying to move forward with a thoughtful, methodical approach", sources quoted Rothenberg as avowing.